Genetic Factors in HPV Infection and Persistence

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on Genetics & Health. Browse all Genetics & Health education

Human papillomavirus (HPV) is extremely common, and in most people the immune system clears it without lasting harm. Why some infections persist while others resolve is partly a question of host genetics — the variations in your own DNA that shape immune recognition and cellular defenses. This article reviews the named gene variants researchers connect to HPV susceptibility and persistence, and explains why genetic context is educational information to discuss with a provider, not a diagnostic or screening tool.

HPV is common; persistence is the key variable

Most sexually active people encounter HPV at some point, and the majority of infections are cleared by the immune system within one to two years. The health concern arises when a high-risk HPV type persists, because long-term persistence is the main driver of the cellular changes associated with certain cancers. Host genetics is one of several factors — alongside HPV type, immune status, and lifestyle — that influence whether an infection clears or lingers.

HLA genes and immune recognition

The human leukocyte antigen (HLA) system presents viral fragments to the immune system so it can mount a response. Because HLA genes are the most variable in the human genome, small differences change how effectively your body 'sees' HPV. Variants in HLA class II genes such as HLA-DQB1 and HLA-DRB1 have been repeatedly associated with differences in HPV clearance and cervical cancer risk in population studies. These associations describe group-level tendencies in immune recognition, not an individual forecast.

TP53 codon 72 (rs1042522)

The TP53 gene encodes p53, a tumor-suppressor protein that helps damaged cells stop dividing. High-risk HPV produces an E6 protein that targets p53 for degradation. A named polymorphism at TP53 codon 72, rs1042522, produces either an arginine or a proline form of the protein. Some studies suggest the arginine form may be more susceptible to E6-mediated degradation, which is why this variant has been investigated in HPV-associated cervical biology. Findings are mixed across populations, underscoring that no single SNP tells the whole story.

Barrier and susceptibility genes

Beyond immune presentation, genes affecting skin and mucosal defense play a role. Rare variants in TMC6 and TMC8 (also called EVER1 and EVER2) cause a condition of heightened susceptibility to specific HPV types, illustrating how epithelial-barrier genetics can shape vulnerability. For the general population, common variation across many genes contributes small, additive effects rather than a single decisive gene — a pattern typical of complex host-pathogen interactions.

What genetics does not replace

None of this substitutes for established prevention and screening. Vaccination, routine cervical screening, and clinical follow-up remain the evidence-based tools for HPV-related health, and decisions about them belong with a qualified provider. Genetic context can add a layer of understanding about your immune and cellular pathways, but it cannot diagnose infection, predict cancer, or take the place of screening.

How pathway-level genetics fits in

Understanding immune and tumor-suppressor pathways is genuinely useful background — the more you know about your biology, the better your questions for your provider. PlexusDx tells you about your biology; it does not tell you what to put in your body or diagnose any condition. That is the appropriate, compliant role for pathway-level genetic education in a topic as clinically important as HPV.

Curious how your own DNA shapes these pathways? The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights to give you pathway-level context you can review with your provider. It reports on your biology — it does not tell you what to put in your body, diagnose any condition, or replace medical care.

Frequently Asked Questions

Can genetic testing tell me if I have HPV?

No. Genetic testing looks at your inherited DNA, not at whether a virus is present. Only HPV-specific testing and clinical screening can detect infection. Host-genetics context describes immune and cellular pathways that research links to clearance tendencies; it does not diagnose HPV or any related condition.

Do HLA genes determine whether I clear HPV?

Not on their own. Variants in HLA-DQB1 and HLA-DRB1 are associated with differences in HPV clearance across populations, but they are one factor among many, including HPV type and immune status. Associations describe group tendencies, not a guaranteed outcome for any individual person.

Should I skip screening if my genetics look favorable?

No. Genetic context never replaces vaccination, cervical screening, or clinical follow-up, which remain the evidence-based tools for HPV-related health. A favorable variant profile does not lower risk enough to change screening guidance. Always follow the recommendations of your qualified healthcare provider.

What does the PlexusDx test tell me here?

It provides pathway-level context about immune and cellular biology to inform a conversation with your provider. It does not diagnose, screen for, treat, or predict HPV or any cancer. It reports on your biology — it does not tell you what to put in your body.

The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use, and it does not diagnose, treat, cure, manage, or prevent any disease or condition. Consult a qualified healthcare provider before beginning any peptide protocol or making changes to your health care.

This article is part of the PlexusDx Education Hub. Browse all Genetics & Health education